|
|
Dragana Noe, Ph.D. received a doctoral degree from the Institute for the Application of Nuclear Energy, INEP (Affiliated to University of Belgrade) in May 2014. With over a decade of experience in the proteomics field, Dr. Dragana Noe serves as a leader and innovator at Precision Biomarker Laboratories within Cedars-Sinai Medical Center. Specializing in targeted proteomics, Dr. Noe leads the development and application of cutting-edge mass spectrometry approaches and technologies. Her efforts aim to deepen our understanding of the world, discover new therapies, and combat life-threatening diseases.
|
Accurate data analysis is pivotal in clinical proteomics for the precise quantification of plasma biomarkers, crucial in both disease detection and monitoring. The majority of targeted proteomics research relies on open-source software, such as Skyline and SmartPeak.
Read More
This study compares Skyline and SmartPeak employing a 60-biomarker Health Surveillance Panel (HSP) in plasma from inflammatory bowel disease (IBD) patients, using an automated highly multiplexed liquid chromatography-targeted mass spectrometry workflow. Our assessments include Limit of Detection (LOD), Limit of Quantification (LOQ), linear range, and endogenous peptide quantification. Our aim is to rigorously compare the performance of Skyline and SmartPeak in analyzing the HSP, highlighting the crucial role of robust data analysis in interpreting plasma biomarkers effectively.
Read Less
